Accelerating nuclear medicine.

Scroll to explore

Actinium-225 offers new possibilities for high-precision cancer treatments.

Tumorous cells are first detected from unique markers on their surface. Once the actinium-225 is attached to the malicious cell, its short-range alpha-emission destroys it, leaving healthy surrounding cells untouched.

Actinium-225 radioligand binding to a cancer-cell receptor A ligand carrying actinium-225 moves into a matching receptor on a cancer cell. A small ring pulses around the payload to suggest radiation. After a pause at binding, the entire cell outline, linker and payload slowly dissolve into small dots that scatter in local bursts. The illustration reforms and repeats; this graphic sequence is not a literal depiction of cell destruction. cancer cell Ac-225

Actinium-225 supply cannot keep pace with growing demand.

Demand outpacing current actinium-225 supply A qualitative illustration: the demand line rises more quickly than the current supply line and the gap widens over time. These curves illustrate the supplied narrative. They do not represent measured values, dates, quantities or a numerical forecast. DemandSupply
Time
Qualitative illustration.

Finite uranium-233 stockpiles and limited radium-226 availability constrain how much existing production routes can deliver.

HI-BEAM is designed to produce actinium-225 at industrial scale.

HI-BEAM combines a high-energy cyclotron, thorium targets and proprietary extraction technology in a system designed to produce actinium-225 at industrial scale.

Supplied HI-BEAM concept rendering, shown in full, including the complete cyclotron and connected beamline.

We use abundant thorium-232, suited for industrial production.

Its low radioactivity makes it easier to handle than radium-226 and doesn't rely on nuclear waste.

Supplied laboratory image showing careful handling of material at an analytical balance.

Our team brings together the expertise to develop HI-BEAM.

Transmutex brings together specialists in nuclear physics, accelerator engineering, chemistry, software and industrial development.

Colleagues working together at laboratory equipment.
Two colleagues collaborating beside control-room monitors.

Management

  • Franklin Servan-Schreiber

    Chief Executive Officer

  • Craig Kelly

    Chief Financial Officer

  • Donovan Maire

    Chief Technical Officer

  • Jean-Christophe de Mestral

    Head of Regulatory and Governmental Affairs

  • Guido Houben

    Managing Director, Transmutex Germany

  • Edouard Servan-Schreiber

    Managing Director, Transmutex USA

  • Michael Daly

    Managing Director, Transmutex Canada

  • Agathe Leclet

    Principal HR Officer

Technical team

  • Alexandre Amorim Carvalho

    Head of Integration Unit

  • Massimo Barbagallo

    Head of Target Unit

  • XiaoXiao Ding

    Head of Quality Assurance

  • Malek Haj Tahar

    Head of Accelerator Unit

  • Karl Johnston

    Head of Extraction Unit

  • Guilhem Lacaze

    Head of Software Unit

  • Monika Sitko

    Head of Planning and Technical Coordination

  • Vasudha Verma

    Head of Nuclear Safety Analyses Unit

Board members

  • Franklin Servan-Schreiber

    Chairman

  • Jean-Christophe de Mestral

    Director

  • Hendrik Höfer

    Director

  • Helen Lin

    Director

  • Victoire Newman

    Director

  • Cameron Porter

    Director

  • Daniel Bertholet

    Observer

  • Brian Steinberg

    Observer

Backed by

Research partners

Your questions about HI-BEAM

Why does the actinium-225 opportunity matter now?

Targeted alpha therapies are advancing rapidly, but actinium-225 supply remains constrained. Transmutex is building the capacity needed for the next stage of clinical and commercial growth.

What sets HI-BEAM apart from existing production routes?

HI-BEAM uses thorium-232, an abundant starting material, instead of relying on scarce uranium-233 inventories or highly radioactive radium-226. It is a production route built to scale.

How much actinium-225 can HI-BEAM produce?

HI-BEAM is designed to produce up to 200 Curies of actinium-225 per year at full capacity.

Has HI-BEAM's technology been validated?

HI-BEAM builds on accelerator and target technologies developed with PSI and CERN, and a thorium irradiation and purification pathway demonstrated at TRIUMF. We are integrating these technologies and optimising the design for large-scale deployment.

When will Transmutex begin supplying actinium-225?

Transmutex is working with laboratory partners on initial supply for research and clinical development by 2028. Full industrial capacity is targeted for 2030.

Contact

Discuss isotope supply, partnerships or investment.

Contact the team

Precision medicine, for everyone